Press releases

Swedish Orphan Biovitrum AB (publ) (Sobi™) announces that the first patient has been dosed in the phase 1/2 study SOBI003-001. The study is an open-label, non-controlled, multiple-dose study with the objective of assessing the safety, tolerability and efficacy of...

08/10/2018 - 09:00
  • Strategic partnership to develop and commercialise emapalumab, a highly attractive late stage orphan drug candidate that addresses a high unmet medical need in primary Haemophagocytic lymphohistiocytosis (HLH)
  • Emapalumab provides an attractive near-term commercial...
07/20/2018 - 08:30

The Annual General Meeting of Swedish Orphan Biovitrum AB (publ) (Sobi™) on 9 May 2018, resolved – for the purpose of ensuring that the company can fulfil its commitments under the long-term incentive programme resolved by the Annual General Meeting – on a directed...

07/18/2018 - 08:10

Swedish Orphan Biovitrum AB (publ) (Sobi™) today announces the results for the second quarter 2018. Total revenues grew 40 per cent compared with Q2 2017 (36 per cent at constant exchange rates, CER) and amounted to SEK 2,289 M. EBITA was SEK 951 M, an increase of 94...

07/18/2018 - 08:00

On 18 July, at 08:00 CET, Swedish Orphan Biovitrum AB (publ) (Sobi™) will publish its report for the second quarter 2018.

Financial analysts and media are invited to participate in a telephone conference, which will include a presentation of the results, on the same day...

07/02/2018 - 11:00

Press contacts

Subscribe to our press releases and financial reports